1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Cancer Vaccines Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Cancer Vaccines Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 Increase in Prevalence of Cancer Worldwide
5.2 Market Opportunities
- 5.2.1 Growing Research and Development Activities
5.3 Future Trends
- 5.3.1 Emerging Markets in Developing Countries
5.4 Impact of Drivers and Restraints
6. Europe Cancer Vaccines Market Regional Analysis
6.1 Europe Cancer Vaccines Market Overview
6.2 Europe Cancer Vaccines Market Revenue 2017-2027 (US$ Million)
6.3 Europe Cancer Vaccines Market Forecast Analysis
7. Europe Cancer Vaccines Market Analysis – by Technology
7.1 Dendritic Cells Cancer Vaccines
- 7.1.1 Overview
- 7.1.2 Dendritic Cells Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Recombinant Cancer Vaccines
- 7.2.1 Overview
- 7.2.2 Recombinant Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Antigen Cancer Vaccines
- 7.3.1 Overview
- 7.3.2 Antigen Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Whole Cell Cancer Vaccines
- 7.4.1 Overview
- 7.4.2 Whole Cell Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Viral Vector Cancer Vaccines
- 7.5.1 Overview
- 7.5.2 Viral Vector Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Cancer Vaccines Market Analysis – by Type
8.1 Preventive Cancer Vaccines
- 8.1.1 Overview
- 8.1.2 Preventive Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Therapeutic Cancer Vaccines
- 8.2.1 Overview
- 8.2.2 Therapeutic Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
9. Europe Cancer Vaccines Market Analysis – by Indication
9.1 Cervical Cancer
- 9.1.1 Overview
- 9.1.2 Therapeutic Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Prostate Cancer
- 9.2.1 Overview
- 9.2.2 Therapeutic Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Other Indications
- 9.3.1 Overview
- 9.3.2 Therapeutic Cancer Vaccines: Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
10. Europe Cancer Vaccines Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Cancer Vaccines Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.1.1.1 Europe Cancer Vaccines Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.1.1 UK: Europe Cancer Vaccines Market Breakdown, by Technology
- 10.1.1.1.2 UK: Europe Cancer Vaccines Market Breakdown, by Type
- 10.1.1.1.3 UK: Europe Cancer Vaccines Market Breakdown, by Indication
- 10.1.1.2 Germany:
Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.2.1 Germany: Europe Cancer Vaccines Market Breakdown, by Technology
- 10.1.1.2.2 Germany: Europe Cancer Vaccines Market Breakdown, by Type
- 10.1.1.2.3 Germany: Europe Cancer Vaccines Market Breakdown, by Indication
- 10.1.1.3 France:
Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.3.1 France: Europe Cancer Vaccines Market Breakdown, by Technology
- 10.1.1.3.2 France: Europe Cancer Vaccines Market Breakdown, by Type
- 10.1.1.3.3 France: Europe Cancer Vaccines Market Breakdown, by Indication
- 10.1.1.4 Russia:
Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.4.1 Russia: Europe Cancer Vaccines Market Breakdown, by Technology
- 10.1.1.4.2 Russia: Europe Cancer Vaccines Market Breakdown, by Type
- 10.1.1.4.3 Russia: Europe Cancer Vaccines Market Breakdown, by Indication
- 10.1.1.5 Italy:
Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.5.1 Italy: Europe Cancer Vaccines Market Breakdown, by Technology
- 10.1.1.5.2 Italy: Europe Cancer Vaccines Market Breakdown, by Type
- 10.1.1.5.3 Italy: Europe Cancer Vaccines Market Breakdown, by Indication
- 10.1.1.6 Rest of Europe:
Europe Cancer Vaccines Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.6.1 Rest of Europe: Europe Cancer Vaccines Market Breakdown, by Technology
- 10.1.1.6.2 Rest of Europe: Europe Cancer Vaccines Market Breakdown, by Type
- 10.1.1.6.3 Rest of Europe: Europe Cancer Vaccines Market Breakdown, by Indication
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Cancer Vaccines Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 AstraZeneca
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Aduro Biotech Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Pfizer Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Sanofi
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Bristol-Myers Squibb
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Moderna, Inc.
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 OncBioMune Pharmaceuticals Inc.
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 MaxiVAX
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Nouscom
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For Europe Cancer Vaccines Market
